The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, on behalf of the TRANSFORMS study group